Author: Su Hang

Translated by: Cao Mi, Wu Xia

On November 18, Chinese Academy of Engineering (CAE) and Chinese Academy of Science (CAS) announced the list of new CAE academicians. Xu Binghe, Grade 1977 alumnus of WHU in clinical medicine, was elected as new CAE academician.

Born in February 1958, Xu Binghe is the chief physician, professor and doctoral supervisor. Xu Binghe always says, “never regard advanced breast cancer as terminal disease.” At the same time, he has also been spearheading the development and clinical trials of new drugs for malignant tumors.

Xu has been engaged in the clinical research and basic research in medical oncology for a long time. He focuses on the cutting-edge theoretical and technical research in the field of breast cancer, and has led his team to conduct a series of pioneering research in the screening and early diagnosis of breast cancer. He established individualized breast cancer screening based on risk assessment with ultrasound and X-ray, which is suitable for China's national conditions and the characteristics of female breast. He also established precise and individualized treatment strategy based on molecular typing and proposed a new research direction for solving resistance of tumor drug. In the past 5 years, he has led a series of clinical trials of new anti-tumor drugs and participated in more than 100 clinical trials of new drugs as the lead PI in China, which greatly contributes to the innovative research and development of anti-tumor drugs in China.